[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100416358":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":21,"interventions":27,"overallOfficials":13,"centralContacts":30,"locations":13,"responsibleParty":41,"collaborators":13,"id":43,"slug":13,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":13,"studyType":56,"phases":57,"briefSummary":58,"conditions":59,"keywords":13,"overallStatus":62,"whyStopped":13,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":13},{"fullName":5,"class":6},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Immuno-inflammatory profile description in patients with ischemic stroke and eligible for reperfusion treatment","Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA preconfigurated panels for inflammatory biomarkers.","Up to year",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":17,"primaryPurpose":18,"observationalModel":13,"timePerspective":13,"maskingInfo":19},"NA","SINGLE_GROUP","All patients undergoing a reperfusion procedure as part of an ischemia stroke will be able to participate in the study.","OTHER",{"masking":20,"maskingDescription":13,"whoMasked":13},"NONE",[22],{"label":23,"type":18,"description":24,"interventionNames":25},"Immuno-inflammatory profile description in patients with ischemic stroke","Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers",[26],"Other: Immuno-inflammatory profile description in patients with ischemic stroke",[28],{"type":18,"name":23,"description":24,"armGroupLabels":29,"otherNames":13},[23],[31,37],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Benjamin MAIER, Professor, MD, PhD","CONTACT","01 48 03 65 56","+ 33","bmaier@for.paris",{"name":38,"role":33,"phone":39,"phoneExt":35,"email":40},"Amélie YAVCHITZ, MD, PhD","01 48 03 64 54","ayavchitz@for.paris",{"type":42,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100416358",false,"NCT04701619","Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE)","Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies","IMMUNOSTROKE","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Presenting with an ACS for which reperfusion therapy is indicated according to European and North American recommendations (IV thrombolysis or mechanical thrombectomy or a combination of both)\n* Having received informed information about the study and having signed a consent form to participate in the study (if this is not possible: information and consent from a trusted person or family member if present; emergency inclusion if absent)\n* Affiliated with or beneficiary of a social security system\n\nExclusion Criteria:\n\n* Contraindication to performing a brain MRI (claustrophobia, pacemaker, or other implantable device contraindicating the performance of an MRI)\n* Intracranial hemorrhage associated with AIC on initial imaging\n\nImmunosuppressive treatment or corticosteroid therapy at patient admission\n\n* Pre-existing neurological disability limiting neurological assessment at 3 months (mRS\\>2 at admission)\n* Known and diagnosed dementia pre-existing at the time of the AIC\n* Absolute or relative contraindication to the injection of gadolinium (history of true allergic reaction or intolerance to gadobutrol, renal failure with creatinine clearance \\\u003C15mL\u002Fmin, pregnant or breastfeeding women)\n* Patient treated by another institution and referred solely for mechanical thrombectomy\n* Patient benefiting from legal protection measures","ALL","18 Years","90 Years",{"count":54,"type":55},300,"ESTIMATED","INTERVENTIONAL",[15],"IMMUNOSTROKE study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the course of AIC management by reperfusion treatment and to monitor changes in these different parameters over time. Post-hoc analyses will make it possible to correlate the immuno-inflammatory and thrombo-inflammatory profiles and their evolution with the clinical outcome in terms of post-AIC functional and cognitive disability.",[60,61],"Stroke","Ischemic Stroke","NOT_YET_RECRUITING","2026-01-16",{"date":65,"type":66},"2026-01-20","ACTUAL",{"date":68,"type":55},"2026-09-15",{"date":70,"type":55},"2028-05-15",{"name":5,"class":6}]